---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041287"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:44:34.665910+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q2 net loss $34.2M; terminates MDS/AML programs, delays ALTA-002 IND

## Summary
- GAAP net loss $34.2M ($0.84/share); non-GAAP net loss $27.9M vs $27.1M prior year.
- Cash $224.5M; funding expected through mid-2025 plus $40M term loan availability.
- Terminating ASPEN-02 (MDS) and ASPEN-05 (AML); evorpacept+azacitidine did not improve outcomes.
- ASPEN-06 (gastric cancer) on track for Q4 2023 data update; EU orphan drug designation received.
- ALTA-002 IND delayed to Q1 2024 due to CMC issues; ADC platform expansion deferred.

## SEC filing metadata
- accession: 0000950170-23-041287
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017023041287/0000950170-23-041287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017023041287/alxo-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041287
- JSON: https://secwatch.observer/filing/0000950170-23-041287.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041287.txt

## Key facts
- Earnings Releases
  ALX ONCOLOGY HOLDINGS INC reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023041287/0000950170-23-041287-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.